Abstract
The molecular basis for downregulation of the KAI1 metastasis suppressor gene in invasive and metastatic human cancers is unknown. We have used bisulphite methylation analysis of DNA from paraffin-embedded invasive bladder tumour samples and from bladder cancer cell lines to determine if hypermethylation of a CpG island within the KAI1 promoter is responsible for this effect. Representative invasive tumour cell lines were also exposed to 5-aza-2-deoxycytidine. We found no evidence for hypermethylation of the CpG island and suggest that mechanisms other than promoter hypermethylation are responsible for reduced KAI1 expression in invasive bladder tumours and tumour cell lines.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antigens, CD*
-
Antimetabolites, Antineoplastic / therapeutic use
-
Azacitidine / therapeutic use
-
Base Sequence
-
Carcinoma, Transitional Cell / drug therapy
-
Carcinoma, Transitional Cell / genetics*
-
Carcinoma, Transitional Cell / metabolism
-
Carcinoma, Transitional Cell / pathology
-
CpG Islands / genetics*
-
Down-Regulation
-
Gene Expression Regulation, Neoplastic
-
Humans
-
In Situ Hybridization
-
Kangai-1 Protein
-
Membrane Glycoproteins*
-
Methylation
-
Molecular Sequence Data
-
Neoplasm Invasiveness
-
Promoter Regions, Genetic / genetics*
-
Proto-Oncogene Proteins*
-
RNA, Messenger / metabolism
-
Reverse Transcriptase Polymerase Chain Reaction
-
Tumor Cells, Cultured
-
Urinary Bladder Neoplasms / drug therapy
-
Urinary Bladder Neoplasms / genetics*
-
Urinary Bladder Neoplasms / metabolism
-
Urinary Bladder Neoplasms / pathology
Substances
-
Antigens, CD
-
Antimetabolites, Antineoplastic
-
CD82 protein, human
-
Kangai-1 Protein
-
Membrane Glycoproteins
-
Proto-Oncogene Proteins
-
RNA, Messenger
-
Azacitidine